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 Abstract  
 
Introduction: The effect of parenteral fish oil in septic patients is not widely 
studied. This study investigated the effects of parenteral fish oil on plasma 
phospholipid fatty acids, inflammatory mediators, and clinical outcomes. 
 
Methods: Twenty-five patients with systemic inflammatory response syndrome 
or sepsis, and predicted to need parenteral nutrition were randomized to receive 
either a 50:50 mixture of medium-chain fatty acids and soybean oil or a 
50:40:10 mixture of medium-chain fatty acids, soybean oil and fish oil. 
Parenteral nutrition was administrated continuously for five days from 
admission. Cytokines and eicosanoids were measured in plasma and in 
lipopolysaccharide-stimulated whole blood culture supernatants. Fatty acids 
were measured in plasma phosphatidylcholine. 
 
Results: Fish oil increased eicosapentaenoic acid in plasma 
phosphatidylcholine (P <0.001). Plasma interleukin (IL)-6 concentration 
decreased significantly more, and IL-10 significantly less, in the fish oil group 
(both P <0.001). At Day 6 the ratio PO2/FiO2 was significantly higher in the fish 
oil group (P = 0.047) and there were fewer patients with PO2/FiO2 <200 and 
<300 in the fish oil group (P = 0.001 and P = 0.015, respectively). Days of 
ventilation, length of intensive care unit (ICU) stay and mortality were not 
different between the two groups. The fish oil group tended to have a shorter 
length of hospital stay (22 ± 7 vs. 55 ± 16 days; P = 0.079) which became 
significant (28 ± 9 vs. 82 ± 19 days; P = 0.044) when only surviving patients 
were included.  
 
Conclusions: Inclusion of fish oil in parenteral nutrition provided to septic ICU 
patients increases plasma eicosapentaenoic acid, modifies inflammatory 
cytokine concentrations and improves gas exchange. These changes are 
associated with a tendency towards shorter length of hospital stay.   
Clinical Trials Registration Number ISRCTN89432944 
 
 © 2009  Barbosa et al.; licensee BioMed Central Ltd. This is an open access 
article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is 
properly cited. 
 
 
Introduction {Level 1 heading} 
 
Sepsis results from a host inflammatory response to infection [1] and is 
characterised by high circulating concentrations of inflammatory cytokines such 
as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-8 [1, 2]. 
Although conditions other than infections can trigger a state of 
hyperinflammation, sepsis requires special attention since even with current 
treatments it is often associated with very high mortality. Between  the years 
1979 and 2000, total sepsis-related mortality in the United States rose from 22 
to 44 per 100,000 population [3], accounting for 9% of the overall annual 
mortality [4, 5] with an enormous economic cost [6]. 
 
Septic patients receive the bulk of their nutrition by the parenteral route. 
Recently there has been increased interest in the lipid component of parenteral 
nutrition with the realisation that this not only supplies energy and essential 
building blocks, but may also provide molecules (that is, fatty acids) that are 
bioactive [7, 8]. Traditionally used lipid emulsions are based solely upon 
soybean oil, which is rich in the n-6 fatty acid linoleic acid, or a 50:50 mix of 
vegetable oil rich in medium-chain saturated fatty acids and soybean oil (often 
termed MCT/LCT to indicate the mixture of medium chain and long chain 
triglycerides). More recently fish oil, which contains very long chain n-3 fatty 
acids, has been introduced into some lipid emulsions [9, 10]. The rationale is 
partly that n-3 fatty acids act to reduce inflammatory responses [11], which may 
be promoted by an excessive or unbalanced supply of n-6 fatty acids. 
Compared with n-6 fatty acid rich vegetable oil, fish oil reduces the metabolic 
signs of endotoxemia in experimental animals [12], and lowers plasma cytokine 
concentrations [13] and improves survival [12, 14]. Fish oil containing parenteral 
nutrition has been used in surgical patients demonstrating possible 
improvements in immune function [15, 16] and reduced inflammation [16, 17] 
 which have been linked to a shorter stay in the intensive care unit (ICU) [16] 
and in hospital [16, 18]. However there are few studies of fish oil containing lipid 
emulsions in septic patients in the ICU. Tappy et al. [19] demonstrated that 
parenteral fish oil is well tolerated and has only limited metabolic effects in 
critically ill patients, while Antebi et al. [20] showed that the use of fish oil in ICU 
patients requiring total parenteral nutrition may be associated with better liver 
function and improved antioxidant status. In two studies, Mayer et al. [21, 22] 
reported diminished inflammation, including reduced TNF-α, IL-1β, IL-6, IL-8 
and IL-10 production by cultured monocytes, in septic patients receiving a 
soybean oil-fish oil mix compared to those receiving soybean oil alone. These 
two studies did not report any clinical outcomes. Heller et al. [23] reported a 
dose-response effect of parenteral fish oil on antibiotic demand, length of 
hospital stay and mortality in critically ill patients.  However, this latter study was 
not controlled. Recently, Friesecke et al. [24] reported that use of a mixed 
MCT/LCT/fish oil lipid emulsion in critically ill ICU patients had no effect on 
inflammatory markers, or on clinical outcomes including infections, ventilation 
requirement, or ICU or hospital stay compared with MCT/LCT. In contrast, use 
of fish oil in parenteral nutrition in severe pancreatitis patients resulted in a 
decreased inflammatory response, improved respiratory function and shortened 
Continuous Renal Replacement Therapy time [25]. Thus, there is only limited, 
and contradictory, information on the influence of fish oil containing parenteral 
nutrition in septic ICU patients on markers of inflammation and on clinical 
endpoints. However, studies of enteral nutrition providing fish oil, in addition to 
other potentially active ingredients, have demonstrated reduced inflammation, 
improved gas exchange and improved clinical outcome in patients with acute 
respiratory distress syndrome and/or acute lung injury [26-28].  
 
This study was designed to investigate the potential benefits of using a 
parenteral lipid emulsion that includes fish oil in septic patients in the ICU. The 
outcomes were plasma phospholipid fatty acid profile, inflammatory mediators 
in plasma and produced by lipopolysaccharide-stimulated whole blood, routine 
biochemical and physiological markers, gas exchange and clinical outcomes. It 
was hypothesised that inclusion of fish oil would increase the n-3 fatty acid 
 content of plasma phospholipids, would decrease circulating inflammatory 
cytokine concentrations and would reduce length of ICU and hospital stay. 
 
Materials and methods {Level 1 heading} 
 
Study design {Level 2 heading} 
This study was a randomized, single blinded investigation of a parenteral lipid 
emulsion that contained fish oil in comparison with one that did not in patients 
admitted to a medical ICU with diagnosed sepsis. Patients were recruited from 
the ICU of Hospital Padre Américo, Penafiel, Portugal. The study was approved 
by the Ethics Committee Comissão de Ética para a Saúde from Hospital Padre 
Américo and was conducted in accordance with the Helsinki Declaration. 
Written informed consent was obtained from each patient’s closest relative. 
                   
Patient selection {Level 2 heading} 
Twenty-five patients with diagnosed systemic inflammatory response syndrome 
(SIRS) or sepsis [1] and who were predicted to need parenteral nutrition (severe 
pancreatitis, multiorgan failure, excisional surgery) were recruited at the time of 
admission to the ICU. Patients were recruited between March and December 
2007. Sepsis was defined as suspected or proven infection plus SIRS (that is, 
presence of pyrexia, tachycardia, tachypnea and/or leukocytosis). Severe 
sepsis was defined as sepsis with organ dysfunction (hypotension, hypoxemia, 
oliguria, metabolic acidosis, and/or thrombocytopenia). Septic shock was 
defined as severe sepsis with hypotension despite adequate fluid resuscitation. 
Once identified as eligible to enter the study, patients were randomized by a 
sealed envelope to receive either a 50:50 (vol/vol) mixture of an oil rich in 
medium-chain fatty acids and soybean oil (termed MCT/LCT) (provided as a 
component of Nutriflex LipidSpecial®, B.Braun, Barcarena, Portugal) or a 
50:40:10 (vol/vol/vol) mixture of an oil rich in medium-chain fatty acids, soybean 
oil and fish oil (termed fish oil) (provided as Lipolus®, B.Braun, Portugal). The 
principal differences are the presence of the long chain n-3 fatty acids 
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-
3) in the fish oil containing emulsion where they contribute about 3.6% of fatty 
acids (2.5% of fatty acids as EPA and 1.1% of fatty acids as DHA) [29]. Nutriflex 
 LipidSpecial is the routine means for supplying parenteral nutrition in Hospital 
Padre Américo ICU. Nutriflex LipidSpecial provides lipid (MCT/LCT emulsion), 
glucose and amino acids via a 1.25 liter three chamber bag. Lipoplus (250 ml) 
was added into 1 liter Nutriflex Special® (B.Braun, Portugal) two chamber bags 
that provided glucose and amino acids. Nutriflex LipidSpecial had a lower 
glucose content than Nutriflex Special containing Lipoplus (144 g/l vs. 195 g/l), 
while the amino acid content was similar (57.4 g/l vs. 56 g/l). The amount of lipid 
contained within the final mixture was the same in both groups (40 g/l). 
Dipeptiven® (Fresenius-Kabi, Carnaxide, Portugal) (50 ml/1250 ml bag) was 
included in both regimens. Both groups received electrolytes and vitamins.  
 
Two of the 25 patients recruited did not start on parenteral nutrition and so are 
excluded from the study. Characteristics of the 23 patients who started on 
parenteral nutrition in the two groups are summarised in Table 1. From the 23 
patients analysed, 13 received fish oil and 10 received MCT/LCT. Parenteral 
nutrition was administrated continuously over 24 hours, starting on the day after 
admission when the patient was hemodynamically stable, or if not, as soon as 
possible (Day 1 is defined as when parenteral nutrition was started). Blood 
samples were collected on admission, immediately prior to starting parenteral 
nutrition (that is, Day 1), 24 h after initiating parenteral nutrition (Day 2) and five 
days after initiating parenteral nutrition (Day 6). Blood was collected between 
08:30 to 9:00 hours via an arterial line into ethylenediaminetetraacetic acid or 
lithium heparin. 
 
Enteral nutrition was initiated as soon as possible, but for all patients this was 
beyond Day 6; enteral feeding was initiated as a mixed regimen with parenteral 
nutrition which used the same lipid emulsion as had been used for the study 
duration. For all patients the enteral feed used was Fresubin Original (Freseius-
Kabi, Portugal); Fresubin Original contains fish oil and will provide 0.5 g of EPA 
plus DHA per 1,500 kcal.  
 
Nutritional assessment {Level 2 heading} 
Caloric intake was calculated using the Harris-Benedict [30] formula using a 
stress factor between 1.2 and 1.3. Weight was obtained at admission using a 
 Hill-Rom® bed (Hill-Rom Total Care, Batesville, IN, USA) which has a 
previously calibrated balance incorporated. Height was measured with the 
patient lying flat in bed.  
    
Routine laboratory measurements {Level 2 heading} 
Full blood count, biochemistry and coagulation were routinely assessed. Blood 
was centrifuged at 2,000 rpm for 15 minutes to obtain plasma which was stored 
at -70ºC until analysis (within nine months). 
 
Whole blood culture and plasma collection {Level 2 heading} 
Whole blood was cultured essentially as described by Yaqoob et al. [31]. Whole 
blood was collected into lithium heparin and diluted 1:10 in Roswell Park 
Memorial Institute medium with 2 mmol/l L-glutamine and antibiotics (Sigma-
Aldrich, Schnelldorf, Germany). The diluted blood was cultured in duplicate, with 
and without 10 µg/ml of E. coli 0111:B4 lipopolysaccharide (LPS) (Sigma-
Aldrich, Schnelldorf, Germany). Culture plates were incubated for 24 h in a 95% 
air 5%CO2 atmosphere and at 37ºC. After this, the supernatant medium was 
collected and stored at -70ºC until analysis (within nine months). 
 
Cytokine and eicosanoid analyses {Level 2 heading} 
Cytokines, prostaglandin (PG) E2 and leukotriene (LT) B4 were measured in 
plasma and cytokines and PGE2 in whole blood culture supernatants. Cytokines 
and eicosanoids were measured using enzyme-linked immunosorbent assays 
(ELISA) and following the manufacturer’s instructions. IL-1β, IL-6, IL-10 and 
TNF-α ELISA kits were from Invitrogen (Paisley, UK), PGE2 ELISA kits from 
R&D Systems (Abingdon, UK) and LTB4 ELISA kits were from Cayman 
Chemical (Ann Arbor, MI, USA). Lower limits of detection were: IL-1β  0.06 
pg/ml, IL-6 104 fg/ml, IL-10 0.2 pg/ml, TNF-α 0.09 pg/ml, PGE2 27.5 pg/ml, and 
LTB4 4 pg/ml.  
 
Fatty acid composition of plasma phosphatidylcholine {Level 2 heading} 
Fatty acid composition of plasma phospholipids (phosphatidylcholine; PC) was 
determined by gas chromatography as described [32].  
  
Statistical analysis {Level 2 heading} 
Data are presented as mean ± SEM, unless indicated otherwise. Statistical 
analyses were performed using SPSS version 14 (SPSS, Chicago, IL, USA). 
One factor ANOVA was used to analyse changes over time within a treatment 
group. Student’s t-test was used for comparisons between time points and for 
comparisons between groups at a particular time point; equal variances were 
not assumed. Linear correlations were determined as Pearson’s correlation 
coefficients. In all cases, a value of P <0.05 was taken to indicate statistical 
significance.  
 
Results {Level 1 heading} 
 
Energy and nutrient intakes  {Level 2 heading} 
Energy, lipid, and amino acid intakes did not differ significantly between the 
groups (Table 2). However, glucose intake was significantly higher in the fish oil 
group (Table 2). The fish oil group received an average of 6.4 g/d of fish oil 
(Table 2), providing an average of 1.6 g EPA plus 0.7 g DHA/d (that is, 2.3 g 
long chain n-3 fatty acids/d).  
 
Plasma phosphatidylcholine fatty acid composition {Level 2 heading} 
The fatty acid composition of plasma PC was measured as an indicator of n-6 
and n-3 fatty acid status. Plasma PC contributes about 75% of plasma 
phospholipid [33] and functions as a transport pool of fatty acids delivering them 
to target tissues like leukocytes. The concentration of the long chain n-3 fatty 
acid EPA (20:5n-3) was increased in the fish oil group after supplementation 
such that levels were higher at Day 6 than at admission (P < 0.001), at Day 1 (p 
<0.001) and at Day 2 (P = 0.003) (Figure 1a). EPA was higher in the fish oil 
group than in the MCT/LCT group at Day 6 (P <0.001). The concentrations of 
DHA (22:6n-3) and of the long chain n-6 fatty acid arachidonic acid (20:4n-6) 
did not differ between the two groups (Figure 1b and 1c).  
 
Plasma cytokine and eicosanoid concentrations {Level 2 heading} 
 Plasma cytokine, PGE2 and LTB4 concentrations did not differ between the two 
groups prior to initiation of parenteral nutrition (that is, Day 1) (Table 3). Linear 
regression demonstrated that both IL-1β and TNF-α decreased over time in 
both groups (IL-1β: P = 0.035 and P = 0.010 in the MCT/LCT and fish oil groups 
respectively; TNF-α: P = 0.036 and P = 0.005 in the MCT/LCT and fish oil 
groups respectively). Plasma IL-6 concentration also decreased over time in the 
fish oil group (P = 0.023). The changes in concentrations of IL-1β, IL-6, IL-10, 
and TNF-α between Day 6 and Day 1 were significantly different between 
groups when concentration at Day 1 was adjusted for; when concentration at 
Day 1, age and glucose supply were adjusted for; and when concentration at 
Day 1, age, glucose supply and simplified acute physiology score (SAPS) II at 
entry were adjusted for (all P <0.001; Table 3). The decrease in IL-6 
concentration was greater in the fish oil group while the decrease in IL-10 
concentration was smaller in the fish oil group (Table 3). The decreases in IL-1β 
and TNF-α concentrations were similar between the groups, but were 
significantly smaller in the fish oil group (Table 3).  
 
Cytokine and PGE2 production by LPS-stimulated whole blood cultures 
{Level 2 heading} 
Cytokine and PGE2 production by unstimulated and LPS-stimulated whole 
blood cultures did not differ between treatment groups at admission of patients 
or at any time point thereafter, even after controlling for age, glucose supply and 
SAPS II (data not shown). However, there was a significant effect of time, but 
not of treatment and there was no time x treatment interaction, on the LPS-
stimulated production of TNF-α, IL-1β, IL-6 and IL-10 (two-factor ANOVA P = 
0.002, 0.013, 0.001 and 0.008, respectively). Linear regression demonstrated 
that production of each of these cytokines increased with time, with a similar 
increase in both groups (Pearson’s linear correlation coefficient = 0.394 (P < 
0.001), 0.318 (P < 0.001), 0.416 (P < 0.001), 0.286 (P = 0.007) for TNF-α, IL-
1β, IL-6 and IL-10, respectively). 
 
Routine laboratory measurements {Level 2 heading} 
 There were no differences between the treatment groups with regard to blood 
leukocyte numbers, blood glucose concentration, C-reactive protein 
concentration, partial thrombin time, liver enzymes, and total bilirubin (Table 4). 
In the fish oil group blood monocyte numbers were significantly higher at Day 6 
(1.41 + 0.41 x 103/µl) than at admission (0.52 + 0.09 x 103/µl; P = 0.017) and 
Day 2 (0.47 + 0.11 x 103/µl; P = 0.006). However, blood monocyte numbers did 
not differ between treatment groups at any time point. Fibrinogen concentration 
was significantly lower in the fish oil group at Day 2 (Table 4). 
 
Gas exchange {Level 2 heading} 
At Day 6, partial pressure carbon dioxide (PCO2) and the ratio partial pressure 
of oxygen/fraction of inspired oxygen (PO2/FiO2) were significantly higher in the 
fish oil group than in the MCT/LCT group (P = 0.033 and P = 0.047, 
respectively; Table 5), although the latter lost significance when age and 
glucose supply or age, glucose supply and SAPS II at entry were adjusted for. 
The proportions of patients with PO2/FiO2 <200 and <300 at Day 6 were 
significantly lower in the fish oil group than the MCT/LCT group (0% vs. 60% for 
<200 (P = 0.001; χ2 test) and 36% vs. 70% for < 300 (P = 0.015; χ2 test)). 
Conversely the proportion of patients with PO2/FiO2 >300 at Day 6 was 
significantly higher in the fish oil group than the MCT/LCT group (P = 0.015; χ2 
test). No other differences in gas exchange parameters were seen between the 
two groups (Table 5). 
 
Clinical outcomes {Level 2 heading} 
Days of ventilation and length of stay in the ICU were not different between the 
two treatment groups (Table 6). The fish oil group tended to have a shorter 
length of hospital stay than the control group (22 ± 7 vs. 55 ± 16 days; P = 
0.079; Table 6). This tendency remained when age and glucose supply were 
adjusted for (P = 0.062) and became significant when age, glucose supply and 
SAPS II at entry were adjusted for (P = 0.038). Three patients died within the 
course of the intervention (one in the MCT/LCT group and two in the fish oil 
group); all died from multiple organ failure. When data for these three patients 
who died within the first five days was excluded, length of stay remained shorter 
in the fish oil group, but the difference was not significant (P = 0.078 and P = 
 0.130 and 0.070 after adjustments; Table 6). A further five patients died after 
the completion of the intervention period but before Day 28 (three in the 
MCT/LCT group and two in the fish oil group). When data for these five patients 
were also excluded, length of stay was significantly shorter in the fish oil group 
(P = 0.044), although this significance was lost after adjustment for age and 
glucose supply (P = 0.068) or for age, glucose supply and SAPS II at entry (P = 
0.057). Mortality was not different between groups, although 28 day mortality 
tended to be lower in the fish oil group (Table 6). 
  
Discussion {Level 1 heading} 
 
This study set out to evaluate the effects of a lipid emulsion containing a mixture 
of MCT, soybean oil and fish oil on plasma phospholipid fatty acid profile, 
inflammatory mediators in plasma and produced by LPS-stimulated whole 
blood, routine biochemical and physiological markers, gas exchange and 
clinical outcomes in septic patients in the ICU. The control group received a 
50:50 mix of MCT and soybean oil. This is the first study of this fish oil 
containing lipid emulsion (that is, Lipoplus) in septic patients in the ICU, 
although it has been used previously in post-surgery patients [17-19, 34, 35]. In 
these latter patients, Lipoplus was found to decrease production or 
concentration of inflammatory eicosanoids [17, 34] and cytokines [17] and to 
reduce length of hospital stay [18]. A different fish oil containing lipid emulsion 
(Omegaven) has also been used in post-surgery patients where it decreased 
production or concentration of inflammatory eicosanoids [36] and cytokines [16], 
improved immune function [15, 16] and improved clinical outcomes [15, 16, 37]. 
Omegaven has also been used in septic patients [21, 22], in critically ill ICU 
patients [24] and in patients with severe acute pancreatitis [25]. In some of 
these studies, use of Omegaven was associated with decreased inflammatory 
markers [21, 22, 25] and improved respiratory function [25]. Heller et al. [23] 
used Omegaven in a heterogeneous group of patients including post-surgical, 
septic and trauma patients and identified a dose-dependent reduction in 
mortality predicted from SAPS II score at entry. However, a recent study 
reported no effect of parenteral nutrition including Omegaven on inflammatory 
 markers, or on clinical outcomes including infections, ventilation requirement, or 
ICU or hospital stay in critically ill ICU patients [24].  
 
The current study found that five-day infusion of a MCT, soybean oil, fish oil 
mixture providing 6.4 g fish oil/day (equivalent to 2.3 g EPA plus DHA/d), 
increased EPA in the plasma phospholipid PC by an average of 3.8-fold, with 
no significant effect on DHA content and that this was associated with improved 
gas exchange and a tendency towards a shorter length of hospital stay. These 
are important findings since they indicate that the use of such an emulsion in 
this group of patients will improve clinical outcomes in comparison with what is 
seen with the more standard mix of MCT and soybean oil.    
 
The increase in EPA content of PC is consistent with the recent report of a 2.4-
fold increase in EPA in plasma phospholipids in healthy subjects receiving this 
same emulsion over a period of five days [29]. Likewise the lack of a significant 
change in either in DHA or arachidonic acid in plasma PC seen in the current 
study is consistent with what is reported by Simoens et al. [29]. These 
observations would suggest that any clinical benefit seen from the emulsion is 
due to EPA rather than DHA.    
 
The tendency towards a reduction in length of hospital stay seen here (Table 6) 
was not a result of shorter ICU stay, and is consistent with findings in post-
surgery patients receiving parenteral fish oil [15, 16, 18]. A previous study using 
a different lipid emulsion in ICU patients reports reduced ICU stay with higher 
fish oil administration [23] but this study was not controlled and relied upon 
historical data for comparison. Thus, this is the first randomised, controlled 
study reporting reduced length of hospital stay in septic ICU patients as a result 
of use of a fish oil containing lipid emulsion. The average dose of fish oil 
administered in the current study (6.4 g/day or 0.09 g/kg/d) is consistent with 
the dose that Heller et al. [23] found to be clinically favourable (>0.1 g/kg/d). 
 
The current study identified a benefit of parenteral fish oil on gas exchange 
(Table 5). This is consistent with the recent report by Wang et al. [25] using 
parenteral fish oil in severe acute pancreatitis patients and with findings in acute 
 respiratory distress syndrome patients receiving enteral fish oil [26]. The 
mechanism by which n-3 fatty acids improve respiratory function is not entirely 
clear, but recent work in the fat-1 mouse, which endogenously synthesizes n-3 
fatty acids from dietary n-6 fatty acids, provides new information on this [38]. 
When exposed to LPS intratracheally, fat-1 mice showed reduced leukocyte 
invasion, protein leakage and inflammatory mediator (thromboxane B2, 
macrophage inflammatory protein-2) levels in lavage fluid compared with wild 
type mice. Furthermore ventilator compliance was improved in the fat-1 mice. 
This study shows a close link between anti-inflammatory effects of n-3 fatty 
acids, in this case seen at the level of the lung, and improved respiratory 
function. 
 
Patients receiving parenteral fish oil showed more of a marked reduction in 
plasma IL-6 concentration than those in the MCT/LCT group and they also 
showed a smaller reduction in the anti-inflammatory cytokine IL-10. These 
findings concur with observations in post-surgery patients where plasma IL-6 
concentrations were lower with parenteral fish oil [16, 17]. These changes in 
plasma inflammatory markers may be part of the mechanism that explains the 
clinical benefits seen in this study. Differences in plasma TNF-α and IL-1β 
concentrations between the two groups were small, although significant.  
 
In contrast to the effects on some plasma cytokines, parenteral fish oil did not 
affect LPS-stimulated production of inflammatory mediators from whole blood 
cultures. This contrasts with the observation of Mayer et al. [22] in septic ICU 
patients that LPS-stimulated production of inflammatory cytokines (TNF-α, IL-
1β, IL-6, IL-8) by purified monocytes was lower in the fish oil group. However, 
the amount of fish oil and n-3 fatty acids used by Mayer et al. was much greater 
than the amount used in the current study (35 vs. 6.4 g fish oil/d; approximately 
10 vs. 2.3 g EPA plus DHA/d). This may explain the difference in findings 
between the two studies.  
 
In the current study the whole blood cultures responded well to LPS stimulation: 
the response to LPS increased with time in both groups. This is consistent with 
 the recent observations of Kirchhoff et al. [39] who showed increased numbers 
of cytokine-positive monocytes following LPS stimulation of whole blood taken 
from patients with severe multiple injuries over the period 24 to 72 hours post-
admission. Likewise, Heidecke et al. [40] demonstrated that in sepsis survivors 
there is an increase in LPS-stimulated production of IL-1β and IL-10 by 
monocytes over time. This recovery in cellular response appears to be 
associated with improved clinical outcome [39, 40]. The observation that a poor 
inflammatory response of cultured cells taken early in sepsis is associated with 
poor patient outcome [39, 40] seems to conflict with the many observations that 
a poor outcome is associated with higher concentrations of inflammatory 
cytokines in the circulation [41-43]. Thus there seems to be a miss-match 
between circulating pro- and anti-inflammatory cytokine concentrations which 
are elevated early in sepsis and the ability of leukocytes to produce pro- and 
anti-inflammatory cytokines which is impaired early in sepsis. Indeed, the 
current study indicates that, as plasma cytokine concentrations decline over 
time, the ability of leukocytes to produce those same cytokines when stimulated 
with LPS ex vivo increases. This seemingly paradoxical observation may be 
explained by considering the regulatory processes that occur to control 
inflammatory cytokine release. A strong inflammatory stimulus in vivo will lead 
to inflammatory cytokine production with an elevation in plasma cytokine 
concentrations. However, this will lead to negative feedback, for example 
inhibition of monocyte nuclear factor κ B activation [44, 45]. Therefore, upon 
restimulation ex vivo, the monocytes are less responsive [46]. Hence 
monocytes isolated from blood at a time when there is a high concentration of 
cytokines may show a low cytokine response when stimulated and vice versa.  
 
The anti-inflammatory properties of n-3 fatty acids have been described and 
discussed in detail elsewhere [11, 47, 48]. The mechanisms involved include 
effects at the membrane level, on signal transduction pathways leading to 
transcription factor activation and altered patterns of gene expression, and on 
the pattern of lipid mediator generation. The discovery of resolvins generated 
from both EPA and DHA [49] has focussed attention on resolution of 
inflammation as a mechanism of action of n-3 fatty acids and on the differential 
effects of EPA and DHA on inflammatory processes. In the current study status 
 of EPA, but not DHA, was increased in plasma PC, suggesting that the effects 
seen are due to EPA. EPA has been shown to decrease production of 
inflammatory eicosanoids and cytokines [see 11] and is the precursor of 
inflammation resolving resolvin E1 [49]. Thus EPA may exert effects on both the 
generation of inflammatory mediators and on the resolution of inflammatory 
processes.   
 
Whatever the mechanism(s) involved, this study demonstrates that a parenteral 
nutrition regimen including fish oil at the level used here does not impair the 
recovery of the ex vivo response of monocytes, but enhances the reduction in 
plasma IL-6 and diminishes the reduction in plasma IL-10 concentrations seen 
in the control group. Given that poor outcome is associated both with high 
plasma concentrations of inflammatory cytokines, including IL-6 [41-43] and 
with impaired ex vivo monocyte responses to LPS [39, 40], the overall effects of 
fish oil seen in the current study appear to be of benefit.  
 
Limitations of this study are its relatively small sample size, the difference in age 
between the two treatment groups (the average age of patients in the fish oil 
group was higher than in the MCT/LCT group), and the higher glucose supply in 
the fish oil group. However, despite the small sample size, significant effects on 
plasma phospholipid EPA content, plasma cytokines, and gas exchange 
parameters were observed. In order to account for the differences in age and 
glucose supply between the two groups, these were controlled for in statistical 
analysis of cytokines, gas exchange parameters and clinical outcomes. Even 
after accounting for the differences in age and glucose supply between the 
groups, effects of lipid emulsion on plasma cytokines and on gas exchange 
parameters remained significant and the trend for an effect on length of hospital 
stay was not altered.     
 
Conclusions {Level 1 heading} 
 
Inclusion of fish oil in parenteral nutrition provided to septic ICU patients 
increases plasma EPA status and this is associated with more marked changes 
 in some cytokines in plasma, improved gas exchange and a trend towards 
reduced length of hospital stay.   
 
Key messages {Level 1 heading} 
 
• Including fish oil in the parenteral nutrition regimen received by septic 
ICU patients modified plasma IL-6 and IL-10 concentrations. 
• Parenteral fish oil improved gas exchange in septic ICU patients. 
• Parenteral fish oil decreased length of hospital stay in septic ICU 
patients. 
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Tables {Level 1 heading} 
 
Table 1: Characteristics of the patients in the two treatment groups 
 
 Fish oil group 
(n = 13) 
MCT/LCT 
group (n = 10) 
Age range (years) 54 to 80 32 to 79 
Age (years)  70 ± 2* 57 ± 5 
Sex: male/female (n) 5/8 4/6 
Height (m) 1.59 ± 0.1 1.63 ± 0.06 
Weight (kg) 73.3 ± 18.01 76.8 ± 21.28 
Body mass index (kg/m2) 28.9 ± 1.7 28.5 ± 2.6 
 Admitted from: Operating theatre 
/Emergency/Ward (n) 
9/3/1 6/3/1 
SAPS II  47.5 ± 5 41.6 ± 6.5 
Sequential organ failure assessment score 9.5 ± 0.9 8.9 ± 1.2 
Primary diagnosis: Sepsis/Severe sepsis/Septic 
shock (n) 
8/4/1 5/2/3 
Secondary Diagnosis: 
Cardiovascular/Respiratory/ 
Renal/Gastric/Mental/Metabolic (n) 
9/1/1/2/0/0 7/0/2/2/2/1 
Data are shown for patients who received parenteral nutrition (n = 23). 
SAPS - Simplified Acute Physiology Score; *P = 0.019 vs. MCT/LCT 
 
Table 2: Energy and nutrient intake in the two treatment groups 
 
  
Fish oil group MCT/LCT group 
Energy intake (kcal/d) 2057 ± 418 1857 ± 255 
(kcal/kg/d) 29.3 ± 7.6 25.3 ± 5.6 
Amino acid intake† (kcal/d) 329.1 ± 67.0 356.6 ± 50.2 
(g/d) 82.3 ± 16.8 89.2 ± 12.6 
(g/kg/d) 1.17 ± 0.30 1.22 ± 0.28 
Glucose intake (kcal/d) 1151 ± 234** 909.8 ± 125.0 
(g/d) 287.9 ± 58.6** 227.5 ± 31.3 
(g/kg/d) 4.10 ± 1.07* 3.10 ± 0.69 
Total lipid intake (kcal/d) 575.9 ± 117.3 594.2 ± 81.7 
(g/d) 63.9 ± 13.0 66.0 ± 9.1 
(g/kg/d) 0.91 ± 0.24 0.90 ± 0.20 
Lipid intake as fish oil (kcal/d) 57.59 ± 11.7*** 0 
(g/d) 6.4 ± 1.3*** 0 
(g/kg/d) 0.09 ± 0.02*** 0 
Data are mean + SEM; †Excluding glutamine and alanine provided in dipeptiven 
*P = 0.018; **P <0.01; ***P <0.001 vs. MCT/LCT 
 Table 3: Plasma cytokine and eicosanoid concentrations in the two treatment 
groups (pg/ml) 
 
Fish oil group MCT/LCT group  
Day 1 Day 6 – Day 1 Day 1 Day 6 – Day 1 
IL-1β  5.0 ± 3.2 -3.8 ± 3.0* 5.7 ± 2.2 -4.2 ± 2.2 
IL-6  8181 ± 5723 -4950 ± 6690* 1499 ± 732 -1242 ± 725 
IL-10  44 ± 8 -29 ± 8* 85 ± 44 -64 ± 40 
TNF-α  18.0 ± 3.1 -8.1 ± 3.6* 18.5 ± 5.1 -9.6 ± 4.9 
PGE2 267 ± 126 391 ± 393 210 ± 134 513  ± 471 
LTB4  338 ± 88 111 ± 147 421 ± 160 271 ± 148 
Data are mean + SEM 
*P < 0.001 vs MCT/LCT group after adjusting for Day 1 value, or for Day 1 
value, age and glucose supply, or for Day 1 value, age, glucose supply and 
SAPS II at entry. 
 
 
 
Table 4: Routine laboratory parameters in the two treatment groups 
 Fish oil group MCT/LCT group 
 Admissio
n 
(n =13) 
Day 1 
(n = 13) 
Day 2 
(n =13) 
Day 6 
(n = 11) 
Admission 
(n = 10) 
Day 1 
(n = 10) 
Day 2 
(n = 10) 
Day 6 
(n = 10) 
Leucocytes 
(103/µL) 
14.6 ± 7.4 
 
16.2 ± 
9.2 
14.2 ± 
6.8 
11.8 ± 5.4 17.7 ± 
13.2 
18.6 ± 
12.8 
15.2 ± 
9.7 
12.0 ± 
6.0 
Platelets 
(103/µL) 
212 ± 158 
 
180 ± 
163 
126 ± 
138 
138 ± 122 215 ± 131 241 ± 
122 
204 ± 
109 
223 ± 
150 
Partial 
thrombin time 
(seconds) 
46.2 ± 
14.8 
55.9 ± 
21.5 
66.5 ± 
41.5 
77.1 ± 
94.5 
38 ± 18.8 44.6 ± 
20.7 
40.6 ± 
12.8 
34.8 ± 
6.6 
Fibrinogen 
(mg/dL) 
271 ± 136 
 
286 ± 
137 
290 ± 
159* 
410 ± 94 428 ± 202 444 ± 
184 
481 ± 
123 
469 ± 76 
Glucose 149 ±  84 149 ± 53 206 ± 71 160 ± 35 139 ± 36 138 ± 48 177 ± 47 185 ± 69 
 (mg/dL)  
CRP (mg/L) 177 ± 91 
 
194 ± 
110 
215 ± 98 118 ± 53 182 ± 124 241 ± 
105 
239 ± 85 150 ± 
108 
AST (UI/L) 102 ± 99 
 
86 ± 86 80 ± 64 48 ± 36 53 ± 41 51 ± 45 37 ± 33 37 ± 17 
ALT (UI/L) 
 
46.5 ± 
51.4 
40.3 ± 
44.1 
49.1 ± 
52.8 
45.9 ± 
57.0 
36.6 ± 
29.7 
32.2 ± 
25.0 
25.7 ± 
20.6 
77.0± 
157.8 
GGT (UI/L) 
 
90.8 ± 
107.9 
89.5 ± 
166.3 
77.4 ± 
134.2 
129.9 ± 
116.0 
122.9 ± 
120.0 
92.3 ± 
103.0 
75.8 ± 
75.2 
103.4 ± 
67.7 
Bilirubin 
(mg/dL) 
2.1 ± 0.7 
 
2.4 ± 0.6 2.8 ± 0.8 3.0 ± 0.8 1.3 ± 0.4 1.3 ± 0.4 1.4 ± 0.3 1.6 ± 0.8 
Data are mean + SEM 
CRP = C-reactive protein; AST = Aspartate transaminase; ALT = Alanine 
transaminase; GGT = γ-glutamyl transpeptidase 
*P = 0.024 vs. MCT/LCT at the same timepoint 
 
Table 5: Gas exchange parameters in the two treatment groups 
Data are mean + SEM, apart from PEEP values, which are median and interquartile 
range.  
PO2  = partial pressure of oxygen; PCO2  = partial pressure of carbon dioxide; FiO2  = 
fraction of inspired oxygen; PEEP = positive end-expiratory pressure; *P = 0.033 vs. 
MCT/LCT group at the same timepoint (Student’s t-test with equal variances not 
                                        Fish oil group MCT/LCT group 
 Admission 
(n = 13) 
Day 1 
(n = 13) 
Day 2 
(n = 13) 
Day 6 
(n = 11) 
Admission 
(n = 10) 
Day 1 
(n = 10) 
Day 2 
(n = 10) 
Day 6 
(n = 10) 
pH 7.27 ± 
0.15 
7.38 ± 
0.11 
7.41 ± 
0.12 
7.42 ± 
0.06 
7.37 ± 
0.09 
7.38 ± 
0.11 
7.44 ± 
0.06 
7.43 ± 0.1
Lactate (mmol/L) 3.2 ± 1.8 4.0 ± 1.7 4.5 ± 4.8 1.9 ± 0.7 2.7 ± 1.9 3.3 ± 1.9 2.4 ± 1.2 3.1 ± 2.7 
PO2 (mm Hg) 198 ± 121 138 ± 45 127 ± 42 132 ± 44 178 ± 80 136 ± 42 145 ± 33 112 ± 38 
PCO2 (mm Hg) 78 ± 125 39 ± 7 41± 6 48 ± 8* 36 ± 8 39 ± 10 40 ± 8 40 ± 8 
PO2/FiO2 269 ± 125 248 ± 81 253 ± 
102 
331 ± 
71** 
262 ± 132 252 ± 
125 
299 ± 80 245 ± 107
PEEP (cm H20) 5 (5, 7) 5 (5, 7) 5 (5, 7) 5 (5, 9) 5 (5, 6) 5 (5, 7) 5 (5, 6) 5 (5, 8) 
 assumed; P = 0.016 after adjusting for age and glucose supply; P = 0.027 after adjusting 
for age, glucose supply and SAPS II at entry); **P = 0.047 vs. MCT/LCT group at the 
same timepoint (Student’s t-test with equal variances not assumed; P = NS after adjusting 
for age and glucose supply or for age, glucose supply and SAPS II at entry). 
 
Table 6: Clinical outcomes in the two treatment groups 
Data are mean + SEM, apart from mortality values 
*P = 0.079 vs. MCT/LCT (Student’s t-test with equal variances not assumed; P 
= 0.062 after adjusting for age and glucose supply; P = 0.038 after adjusting for 
age, glucose supply and SAPS II at entry); 
**P = 0.078 vs. MCT/LCT (Student’s t-test with equal variances not assumed; P 
= 0.130 after adjusting for age and glucose supply; P = 0.070 after adjusting for 
age, glucose supply and SAPS II at entry); 
*** P = 0.044 vs. MCT/LCT (Student’s t-test with equal variances not assumed; 
P = 0.068 after adjusting for age and glucose supply; P = 0.057 after adjusting 
for age, glucose supply and SAPS II at entry) 
 
 
                                                   Fish oil group 
(n = 13) 
MCT/LCT group 
(n = 10) 
 
Ventilated days 
(excluding three patients who died in 
<5 days) 
10 ± 4 
(11 ± 5) 
11 ± 4 
(12 ± 4) 
ICU stay (days) 
(excluding three patients who died in 
<5 days) 
12 ± 4 
(14 ± 5) 
13 ± 4 
(14 ± 4) 
Length of hospital stay (days) 
(excluding three patients who died in 
<5 days) 
(excluding all eight patients who died) 
22 ± 7* 
25 ± 8** 
28 ± 9*** 
55 ± 16 
61 ± 17 
82 ± 19 
five day mortality 15% (2 out of 13) 10% (1 out of 10) 
28 day mortality  31 % (4 out of 13) 40% (4 out of 10) 
  
Figure legend {Level 1 heading} 
 
Figure 1 
The concentrations (µg/ml) of (a) EPA, (b) DHA and (c) arachidonic acid in 
plasma phosphatidylcholine in the two treatment groups. *P <0.001 vs. 
MCT/LCT at the same timepoint. 
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